The global stereotactic surgery devices market size accounted for USD 29.76 billion in 2024, grew to USD 30.98 billion in 2025 and is projected to surpass around USD 44.48 billion by 2034, representing a healthy CAGR of 4.10% between 2024 and 2034. The North America stereotactic surgery devices market size is worth around USD 13.69 billion in 2024 and is expected to grow at a fastest CAGR of 4.21% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Stereotactic Surgery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Stereotactic Surgery Devices Market Revenue and Volume, by Product, 2024-2034
8.1.1. Gamma Knife
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. LINAC
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. PBRT
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. CyberKnife
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Stereotactic Surgery Devices Market Revenue and Volume, by Application, 2024-2034
9.1.1. Liver
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Breast
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Prostate
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Lung
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Colon
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1. Medtronic plc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Elekta AB
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Varian Medical Systems, Inc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Brainlab AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Accuray Incorporated
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Renishaw plc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Micromar Indústria e Comércio Ltda.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Alliance Oncology
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Möller Medical GmbH
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Leica Microsystems (Danaher Corporation)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client